Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Vaccines

Free Subscription 07.11.2022 1 BMC Pediatr 1 BMJ 3 Clin Infect Dis 3 J Infect Dis 1 Lancet 3 MMWR Morb Mortal Wkly Rep 1 N Engl J Med 2 Nat Immunol 1 Nat Med 1 PLoS Comput Biol 8 PLoS One 1 Proc Natl Acad Sci U S A 2 Science 8 Vaccine 1 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Pediatr

1. JACKSON C, Nielsen SM, Simonyan B, Kirakosyan M, et al
   Medical specialists' attitudes and practices towards childhood vaccination: a qualitative study in Armenia.
   BMC Pediatr. 2022;22:620.
   PubMed         Abstract available
   
   

   
   BMJ

2. O'DOWD A
   Flu: Public urged to get vaccinated in face of possible surge of infections this winter.
   BMJ. 2022;379:o2655.
   PubMed        
   
   

   
   Clin Infect Dis

3. SIEGHART D, Hana CA, Haslacher H, Perkmann T, et al
   MULTI-PARAMETRIC PREDICTION MODELS FOR COVID-19 VACCINE SELECTION: RESULTS OF A COMPARATIVE POPULATION-BASED COHORT STUDY.
   Clin Infect Dis. 2022 Nov 4. pii: 6795267. doi: 10.1093.
   PubMed         Abstract available
   
   
4. TENFORDE MW, Patel MM, Lewis NM, Adams K, et al
   Vaccine effectiveness against influenza A(H3N2)-associated hospitalized illness, United States, 2022.
   Clin Infect Dis. 2022 Nov 3. pii: 6795261. doi: 10.1093.
   PubMed         Abstract available
   
   
5. BETTINGER JA, Irvine MA, Shulha HP, Valiquette L, et al
   Adverse Events Following Immunization with mRNA and Viral Vector Vaccines in Individuals with Previous SARS-CoV-2 Infection from the Canadian National Vaccine Safety Network.
   Clin Infect Dis. 2022 Oct 31. pii: 6780916. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect Dis

6. JAGER M, Dichtl S, Bellmann-Weiler R, Reindl M, et al
   Serum neutralization against SARS-CoV-2 variants is heterogenic and depends on vaccination regimen.
   J Infect Dis. 2022 Nov 1. pii: 6783141. doi: 10.1093.
   PubMed         Abstract available
   
   
7. KUO TY, Lien CE, Lin YJ, Lin MY, et al
   Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
   J Infect Dis. 2022;226:1562-1567.
   PubMed         Abstract available
   
   
8. MIDDLETON BF, Danchin M, Jones MA, Leach AJ, et al
   Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial.
   J Infect Dis. 2022;226:1537-1544.
   PubMed         Abstract available
   
   

   
   Lancet

9. OPEL DJ, Brewer NT, Buttenheim AM, Callaghan T, et al
   The legacy of the COVID-19 pandemic for childhood vaccination in the USA.
   Lancet. 2022 Oct 26. pii: S0140-6736(22)01693.
   PubMed        
   
   

   
   MMWR Morb Mortal Wkly Rep

10. HAUSE AM, Marquez P, Zhang B, Myers TR, et al
    Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged >/=12 Years - United States, August 31-October 23, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1401-1406.
    PubMed         Abstract available
    
    
11. RACHLIN A, Danovaro-Holliday MC, Murphy P, Sodha SV, et al
    Routine Vaccination Coverage - Worldwide, 2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:1396-1400.
    PubMed         Abstract available
    
    
12. BOEHMER TK, Koumans EH, Skillen EL, Kappelman MD, et al
    Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 - United States, January-July 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1359-1365.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. CHEMAITELLY H, AlMukdad S, Ayoub HH, Altarawneh HN, et al
    Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
    N Engl J Med. 2022 Nov 2. doi: 10.1056/NEJMoa2210058.
    PubMed         Abstract available
    
    

    
    Nat Immunol

14. FOURATI S, Tomalin LE, Mule MP, Chawla DG, et al
    Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination.
    Nat Immunol. 2022 Oct 31. pii: 10.1038/s41590-022-01329.
    PubMed         Abstract available
    
    
15. HAGAN T, Gerritsen B, Tomalin LE, Fourati S, et al
    Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses.
    Nat Immunol. 2022 Oct 31. pii: 10.1038/s41590-022-01328.
    PubMed         Abstract available
    
    

    
    Nat Med

16. CARVALHO T
    Intranasal COVID-19 vaccine fails to induce mucosal immunity.
    Nat Med. 2022 Nov 3. pii: 10.1038/d41591-022-00106.
    PubMed        
    
    

    
    PLoS Comput Biol

17. LEWITUS E, Hoang J, Li Y, Bai H, et al
    Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens.
    PLoS Comput Biol. 2022;18:e1010624.
    PubMed         Abstract available
    
    

    
    PLoS One

18. MAINA D, Omuse G, Ong'ete G, Mugaine P, et al
    Seroprevalence, correlates and kinetics of SARS-CoV-2 nucleocapsid IgG antibody in healthcare workers and nonclinical staff at a tertiary hospital: A prevaccine census study.
    PLoS One. 2022;17:e0267619.
    PubMed         Abstract available
    
    
19. KIM M, Kim JH, Jung YW, Seong SJ, et al
    Gynecologic problems and healthcare behavior by shift patterns in Korean nursing staff.
    PLoS One. 2022;17:e0276282.
    PubMed         Abstract available
    
    
20. GANESAN S, Acosta H, Brigolin C, Orange K, et al
    Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
    PLoS One. 2022;17:e0272594.
    PubMed         Abstract available
    
    
21. GETACHEW D, Yosef T, Solomon N, Tesfaye M, et al
    Predictors of unwillingness to receive COVID -19 vaccines among Ethiopian Medical students.
    PLoS One. 2022;17:e0276857.
    PubMed         Abstract available
    
    
22. AYNALEM ZB, Bogale TW, Bantie GM, Ayalew AF, et al
    Factors associated with willingness to take COVID-19 vaccine among pregnant women at Gondar town, Northwest Ethiopia: A multicenter institution-based cross-sectional study.
    PLoS One. 2022;17:e0276763.
    PubMed         Abstract available
    
    
23. ABDELHAMID MHM, Almsellati IA, Annajar BB, Abdulhamid AH, et al
    Hospitalization among vaccines for SARS-CoV-2 breakthrough infection after dose sparing strategies in Libya: A cohort study.
    PLoS One. 2022;17:e0276425.
    PubMed         Abstract available
    
    
24. FERNANDEZ-SUAREZ A, Jimenez Coronado R, Clavijo Aroca C, Navarro Martin E, et al
    New insights into antibody levels against SARS-CoV-2 for healthcare personnel vaccinated with tozinameran (Comirnaty).
    PLoS One. 2022;17:e0276968.
    PubMed         Abstract available
    
    
25. GOMBE B, Streatfield C, Leal L, Opio S, et al
    Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial.
    PLoS One. 2022;17:e0275927.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

26. MCMAHON M, O'Dell G, Tan J, Sarkozy A, et al
    Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses.
    Proc Natl Acad Sci U S A. 2022;119:e2206333119.
    PubMed         Abstract available
    
    

    
    Science

27. COUZIN-FRANKEL J
    Heart risks fuel debate over COVID-19 boosters.
    Science. 2022;378:234-235.
    PubMed         Abstract available
    
    
28. TORRENTS DE LA PENA A, Sliepen K, Eshun-Wilson L, Newby ML, et al
    Structure of the hepatitis C virus E1E2 glycoprotein complex.
    Science. 2022;378:263-269.
    PubMed         Abstract available
    
    

    
    Vaccine

29. SUN R, Budhwani H
    Negative sentiments toward novel coronavirus (COVID-19) vaccines.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01297.
    PubMed         Abstract available
    
    
30. HEYERDAHL LW, Dielen S, Dodion H, Van Riet C, et al
    Strategic silences, eroded trust: The impact of divergent COVID-19 vaccine sentiments on healthcare workers' relations with peers and patients.
    Vaccine. 2022 Oct 27. pii: S0264-410X(22)01306.
    PubMed         Abstract available
    
    
31. XIE L, Li Y
    Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development.
    Vaccine. 2022 Oct 29. pii: S0264-410X(22)01311.
    PubMed         Abstract available
    
    
32. THULUVA S, Paradkar V, Gunneri S, Yerroju V, et al
    Safety, tolerability and immunogenicity of Biological E's CORBEVAX vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01308.
    PubMed         Abstract available
    
    
33. TONG C, Liu H, Wang J, Sun Y, et al
    Safety, efficacy, and DIVA feasibility on a novel live attenuated CSFV marker vaccine candidate.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01293.
    PubMed         Abstract available
    
    
34. KUNASEKARAN M, Poulos CJ, Chughtai AA, Heslop DJ, et al
    Factors associated with repeated influenza vaccine uptake among aged care staff in an Australian sample from 2017 to 2019.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00981.
    PubMed         Abstract available
    
    
35. KUNASEKARAN M, Moa A, Hooshmand E, Trent M, et al
    Effectiveness estimates for enhanced trivalent influenza vaccines in an aged care summer outbreak.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00766.
    PubMed         Abstract available
    
    
36. ARRIETA A, Garcia-Prado A, Sarmiento JP, Paz Castro C, et al
    Identifying early adopters of COVID-19 vaccines in Latin America.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01294.
    PubMed         Abstract available
    
    

    
    Virus Res

37. GUPTA D, Parthasarathy H, Sah V, Tandel D, et al
    Inactivation of SARS-CoV-2 by beta-propiolactone causes aggregation of viral particles and loss of antigenic potential.
    Virus Res. 2021;305:198555.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: